Safety and toxicological evaluation of Aflapin®: A novel Boswellia-derived anti-inflammatory product
- 29 September 2010
- journal article
- Published by Taylor & Francis Ltd in Toxicology Mechanisms and Methods
- Vol. 20 (9), 556-563
- https://doi.org/10.3109/15376516.2010.497978
Abstract
Boswellia serrata gum resin has been used for treatment of various ailments in different cultures for thousands of years. Aflapin(®) is a novel synergistic composition derived from B. serrata gum resin (Indian Patent Application No. 2229/CHE/2008). Aflapin is significantly better as an anti-inflammatory agent compared to the Boswellia extracts presently available in the market. To assess the safety of Aflapin, a battery of acute and sub-acute toxicity studies were conducted in various animal models according to the OECD test guidelines. The acute oral LD50 of Aflapin was greater than 5000 mg/kg in female Sprague Dawley (SD) rats. Acute dermal LD50 of Aflapin was greater than 2000 mg/kg in SD rats. A primary dermal irritation study conducted using New Zealand White rabbits indicated that Aflapin is non-irritating to skin. Aflapin caused minimal ocular irritation in a primary eye irritation test conducted on New Zealand Albino rabbits. A repeat dose 28-day sub-acute oral toxicity study in SD rats demonstrated no significant signs of toxicity. Various evaluations including hematology, clinical chemistry, gross necropsy, and histopathology did not show any significant adverse changes. The NOAEL of Aflapin was found to be greater than 2500 mg/kg body weight. These studies demonstrate broad spectrum safety of Aflapin in animal models.This publication has 8 references indexed in Scilit:
- Safety and toxicological evaluation of a novel anti-obesity formulation LI85008F in animalsToxicology Mechanisms and Methods, 2010
- In vivo genotoxicity evaluation of a plant based antiarthritic and anticancer therapeutic agent Boswelic acids in rodentsPhytomedicine, 2009
- Safety and toxicological evaluation of demethylatedcurcuminoids; a novel standardized curcumin productToxicology Mechanisms and Methods, 2009
- A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin® for treatment of osteoarthritis of the kneeArthritis Research & Therapy, 2008
- Open, randomized, controlled clinical trial of Boswellia serrata extract as compared to valdecoxib in osteoarthritis of kneeIndian Journal of Pharmacology, 2007
- Safety and Toxicological Evaluation of a Novel, Standardized 3-O-Acetyl-11-keto-β-Boswellic Acid (AKBA)-EnrichedBoswellia serrataExtract (5-Loxin®)Toxicology Mechanisms and Methods, 2006
- Ancient-modern concordance in Ayurvedic plants: some examples.Environmental Health Perspectives, 1999
- Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agentInflammation Research, 1986